Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Zinbryta

(daclizumab)

ApprovedMonoclonal antibody

Daclizumab is used to treat relapsing-remitting multiple sclerosis (MS), a disease where the immune system attacks nerve cells in the brain and spine, causing symptoms like weakness and vision problems.[2] Zinbryta is currently approved and in use across 27 indications[4].[1]

Zinbryta is one of 694 small molecule programs targeting HIV infection. It is currently in Approved.

27

Indications

52

Total Trials

0

Active Trials

693

Competitors

Pipeline

Status by Indication[4][1]

Indication

HIV InfectionActive, not recruiting

GranulomaActive, not recruiting

ThrombocytopeniaActive, not recruiting

Psoriasis VulgarisActive, not recruiting

Immune System DiseaseUnknown

LeukemiaActive, not recruiting

Kidney TransplantUnknown

Cardiac TransplantActive, not recruiting

FibrosisActive, not recruiting

Relapsing-Remitting Multiple SclerosisUnknown

HIV InfectionPhase 1

Active, not recruiting

GranulomaPhase 2

Active, not recruiting

ThrombocytopeniaPhase 2

Active, not recruiting

Psoriasis VulgarisPhase 1/Phase 2

Active, not recruiting

Immune System DiseasePreclinical

Unknown

LeukemiaPhase 1/Phase 2

Active, not recruiting

Kidney TransplantPreclinical

Unknown

Cardiac TransplantPhase 1

Active, not recruiting

FibrosisApproved

Active, not recruiting

Relapsing-Remitting Multiple SclerosisPreclinical

Unknown

Showing 10 of 26 indications

Competition

Competitive Landscape

1050 competitors in Asthma

#DrugCompanyPhaseTrials

Zinbryta

Veramyst

Singulair

Dupixent

AAzienda U.S.L. 1 di Massa e Carrara

Atrovent

Boehringer Ingelheim

Formoterol Fumarate

Aciphex

Akero Therapeutics

Tylenol

DUPIXENT

Blood Withdrawn

Emergent BioSolutions

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Kidney Transplant6 trials

Pediatric Kidney Transplant Without Calcineurin Inhibitors

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00023231·35 enrolled

Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation After Kidney Transplant

Withdrawn·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00790439

A Study to Assess Immune Response in Pediatric Kidney Transplant Recipients Treated With Daclizumab (Zenapax)

Completed· Roche logo

Roche·Phase 4·NCT02576145·11 enrolled

Show 3 more trials

Study Evaluating Sirolimus in Kidney Transplant Recipients

Completed· Pfizer logo

Pfizer·Phase 3·NCT00195273·61 enrolled

Induction Therapy Study in Live Donor Kidney Transplant Recipients With a Positive Crossmatch

Completed·JJohns Hopkins University·Phase 3·NCT00275509·56 enrolled

Comparing Efficacy and Safety of Steroid Withdrawal With Tacrolimus and MMF With Induction in Children After Kidney Transplantation

Completed· Astellas logo

Astellas·Phase 3·NCT00296348·198 enrolled

Uveitis5 trials

Daclizumab Injections to Treat Non-Infectious Sight-Threatening Uveitis

Completed·NNational Eye Institute (NEI)·Phase 2·NCT00043667·15 enrolled

Daclizumab to Treat Non-Infectious Sight-Threatening Uveitis

Completed·NNational Eye Institute (NEI)·Phase 2·NCT00070759·6 enrolled

Combination Daclizumab/Denileukin Diftitox to Treat Uveitis

Completed·NNational Eye Institute (NEI)·Phase 2·NCT00326508·5 enrolled

Show 2 more trials

Daclizumab and Sirolimus to Treat Uveitis

Completed·NNational Eye Institute (NEI)·Phase 1·NCT00078689·6 enrolled

ANTI-TAC THERAPY FOR UVEITIS

Completed·NNational Eye Institute (NEI)·Phase 1·NCT00001526·15 enrolled

Immunosuppression4 trials

Phase I/II Thymus Transplantation With Immunosuppression #950

Completed·SSumitomo Pharma Switzerland GmbH·Phase 1/2·NCT00579527·14 enrolled

Steroid-Free Versus Steroid-Based Immunosuppression in Pediatric Renal (Kidney) Transplantation

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT00141037·130 enrolled

MMF, Daclizumab and Corticosteroids as Mainstay Immunosuppression in Renal Transplant Patients

Completed·—·Phase 4·NCT00231764·1,760 enrolled

Show 1 more trial

Effect of AC2993 With or Without Immunosuppression on Beta Cell Function in Patients With Type I Diabetes

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT00064714·47 enrolled

Renal Transplantation3 trials

Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Deceased Donor Renal Transplantation

Completed·UUniversity of Miami·Phase 4·NCT00685061·90 enrolled

CamTac Trial:Campath-Tacrolimus vs IL2R MoAb/Tacrolimus/MMF in Renal Transplantation

Completed·EEMagnusson·Phase 4·NCT00246129·123 enrolled

Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Living Donor Renal Transplantation

Completed·UUniversity of Miami·Phase 4·NCT00681343·38 enrolled

Psoriasis Vulgaris2 trials

To Study the Effects of CD25 and Low Dose Cyclosporin in the Treatment of Active Psoriasis Vulgaris

Completed·RRockefeller University·Phase 1/2·NCT00050648·20 enrolled

To Study the Use of Humanized CD25 in Preventing the Relapse of Psoriasis Vulgaris

Completed·RRockefeller University·Phase 1/2·NCT00050661·6 enrolled

27 more indications

Multiple Sclerosis2 trials

Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis

Completed·NNational Institute of Neurological Disorders and Stroke (NINDS)·Phase 2·NCT00071838·16 enrolled

Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis

Completed·PPDL BioPharma, Inc.·Phase 2·NCT00109161·270 enrolled

Heart Transplant2 trials

Use of Daclizumab for the Prevention of Allograft Rejection in Pediatric Heart Transplant Patients

Terminated·—·Phase 1/2·NCT00284531·1 enrolled

A Study of Daclizumab (Zenapax) in Combination With Mycophenolate Mofetil (CellCept) and Sirolimus in Prevention of Acute Rejection in Heart Transplant Participants

Completed· Roche logo

Roche·Phase 4·NCT02554955·36 enrolled

Type 1 Diabetes2 trials

Islet Transplantation for Type 1 Diabetes

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00014911·36 enrolled

New Onset of Type 1 Diabetes Mycophenolate Mofetil-Daclizumab Clinical Trial

Completed·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 2·NCT00100178·126 enrolled

Renal Transplant Recipients2 trials

Daclizumab Versus Thymoglobulin in Renal Transplant Recipients With High Immunological Risk

Completed·UUniversity Hospital, Lille·Phase 3·NCT00682292·227 enrolled

Study Comparing Efficacy and Safety of Mycophenolate Mofetil (Cellcept) With Delayed Introduction of Sirolimus and Discontinuation of Cyclosporine, With Those of Mycophenolate Mofetil and Long Term Continuation of Cyclosporine in Renal Transplant Recipients

Completed· Roche logo

Roche·Phase 3·NCT02686619·237 enrolled

Leukemia2 trials

Monoclonal Antibody Plus Interleukin-2 in Treating Patients With Leukemia or Lymphoma

Completed·RRoger Williams Medical Center·Phase 1/2·NCT00002681·25 enrolled

Anti-Tac for Treatment of Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT00001941·34 enrolled

Medication1 trial

Study to Evaluate the Amount of Medications That May be Removed From the Body During Plasmapheresis

Withdrawn·SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University··NCT00203281

Complication1 trial

HAT in Eye Complications of Behcet's Disease

Completed·NNational Eye Institute (NEI)·Phase 2·NCT00001865·26 enrolled

Ulcerative Colitis1 trial

Humanized Anti-IL-2 Receptor Monoclonal Antibody in Moderate-to-severe Ulcerative Colitis

Completed·FFacet Biotech·Phase 2·NCT00073047·150 enrolled

HIV1 trial

Daclizumab to Treat HIV-Infected Patients

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00080431·10 enrolled

Granuloma1 trial

Daclizumab to Treat Wegener's Granulomatosis

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00040248·75 enrolled

Juvenile Idiopathic Arthritis1 trial

Human Anti-Tac (Daclizumab) to Treat Juvenile Idiopathic Arthritis (JIA)-Associated Uveitis

Completed·NNational Eye Institute (NEI)·Phase 2·NCT00130637·6 enrolled

Asthma1 trial

Study of Daclizumab in Patients With Chronic, Persistent Asthma

Completed·FFacet Biotech·Phase 2·NCT00028288·120 enrolled

Cardiac Transplant1 trial

A Study to Evaluate the Efficacy and Safety of Zenapax in Combination With CellCept, Cyclosporine, and Corticosteroids in Patients Undergoing Cardiac Transplantation

Completed· Roche logo

Roche·Phase 4·NCT00048165·434 enrolled

Safety and Efficacy1 trial

Safety and Efficacy Study of Thymoglobulin Versus IL2 Receptor Antagonists

Completed·MMedical University of South Carolina·N/A·NCT00859131·200 enrolled

Randomized1 trial

Randomized Trial of 2 Antibody Induction Steroid Avoidance Protocols

Completed·UUniversity of Miami·Phase 4·NCT01172418·200 enrolled

Transplant Recipient1 trial

A Trial of Two Daclizumab Dosing Strategies vs. No Induction Treatment With Tacrolimus, Mycophenolate Mofetil , & Steroids for the Prevention of Acute Allograft Rejection in Simultaneous Kidney/Pancreas Transplant Recipients

Completed·UUniversity of Cincinnati·Phase 4·NCT00363116·298 enrolled

Melanoma1 trial

Augmentation of Dendritic Cell-Based Vaccines in Melanoma Patients by Depletion of Regulatory T Cells in Stage IV Melanoma Patients

Completed·RRadboud University Medical Center·Phase 1/2·NCT00847106·15 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab

Terminated· Biogen logo

Biogen·Phase 3·NCT02881567·41 enrolled

Glioblastoma Multiforme1 trial

Chemotherapy, Radiation Therapy, and Vaccine Therapy With Basiliximab in Treating Patients With Glioblastoma Multiforme That Has Been Removed by Surgery

Completed·JJohn Sampson·Phase 1·NCT00626015·16 enrolled

Acute Graft Versus Host Disease1 trial

Methylprednisolone With or Without Daclizumab in Treating Patients With Acute Graft-Versus-Host Disease

Completed·—·Phase 3·NCT00053976·105 enrolled

Bone Marrow Failure1 trial

A Study to Determine Whether Therapy With Daclizumab Will Benefit Patients With Bone Marrow Failure

Terminated·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT00001962·100 enrolled

Fibrosis1 trial

Fibrosis in Renal Allografts

Unknown status·UUniversity Hospital, Antwerp·Phase 4·NCT00493194·100 enrolled

Immune Thrombocytopenia1 trial

Daclizumab to Treat Chronic Immune Thrombocytopenia

Completed·NNational Institutes of Health Clinical Center (CC)·Phase 2·NCT00049725·24 enrolled

Islet Transplantation1 trial

B-Lymphocyte Immunotherapy in Islet Transplantation

Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00468442·2 enrolled

Myelodysplastic Syndrome1 trial

A Randomized Trial of Recombinant Humanized Anti-IL-2 Receptor Antibody (Daclizumab) Versus Antithymocyte Globulin (ATG) to Treat the Cytopenia of Myelodysplastic Syndrome (MDS)

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT00072969·132 enrolled

Stem Cell Transplantation1 trial

Mycophenolate Mofetil, Tacrolimus, Daclizumab, and Donor Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Completed·UUniversity of Maryland, Baltimore·Phase 2·NCT00006350

Age-Related Macular Degeneration1 trial

Infliximab, Sirolimus and Daclizumab to Treat Age-Related Macular Degeneration

Completed·NNational Eye Institute (NEI)·Phase 2·NCT00304954·13 enrolled

Sources

References

[1]
ClinicalTrials.gov — 52 trial records for daclizumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Zinbryta drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — daclizumab compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for daclizumab. EMBL-EBI & Wellcome Sanger Institute.
[5]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Interleukin-2 Receptor Inhibitor[3]
Modality: Monoclonal antibody[3]
Highest Phase: Approved[1]
Company: Roche

Related News